Compare IPST & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPST | ACHV |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 172.0M |
| IPO Year | N/A | 2018 |
| Metric | IPST | ACHV |
|---|---|---|
| Price | $0.38 | $5.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.20 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 3.9M | 1.5M |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $66.39 | N/A |
| Revenue Next Year | $60.33 | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $1.96 |
| 52 Week High | $15.08 | $6.03 |
| Indicator | IPST | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 74.55 |
| Support Level | $0.24 | $4.06 |
| Resistance Level | $0.80 | $5.30 |
| Average True Range (ATR) | 0.11 | 0.30 |
| MACD | 0.04 | 0.24 |
| Stochastic Oscillator | 29.92 | 92.72 |
Heritage Distilling Holding Co Inc is a craft distiller producing, marketing, and selling a diverse line of award-winning craft spirits, including whiskeys, vodkas, gins, rums, and ready-to-drink canned cocktails. The company sells its products through wholesale distribution, directly to consumers through its owned and operated distilleries and tasting rooms located in Washington and Oregon, and by shipping directly to consumers online, where legal. Currently, it sells products in the Pacific Northwest with limited distribution in other states throughout the U.S.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.